In a world where people fear growing old more than growing up, Peter Diamandis is trying to flip the script. And he’s doing it not with lotions or mantras but with molecules—synbio molecules.

Diamandis, who has a knack for making the impossible sound like a long-overdue upgrade, is coming to SynBioBeta 2025 this year with a message: The future of aging is enrobed in synthetic biology. And if you’re not thinking about CRISPR, longevity genes, or cell reprogramming as a key piece of the economic future—well, you’re playing checkers on a chessboard that’s already moved to quantum. Peter will be giving a Keynote Presentation on Thursday, May 8, entitled “A Rallying Call to Work on Longevity”

But he’s not just speaking at the conference. He’s bringing with him a kind of “longevity operating system”—the intellectual output of his recent Longevity Guidebook and the experiential download of the Longevity Platinum Trip, a five-day biotech safari through labs and life-extension startups from Boston to New Hampshire. He’s helping shape a new narrative around aging—one that’s less about wrinkles and more about resilience.

And in case you were wondering: yes, that’s the same Peter Diamandis who launched the XPRIZE and co-founded Singularity University. He’s made a career out of betting on exponential technologies before they’re cool. Now his chips are on aging—and he’s doubling down.

Synthetic Biology Is the New Healthcare System

Let me be blunt: Healthcare isn’t ready for what synthetic biology is about to deliver. We’re used to treating disease when it shows up; synthetic biology wants to make disease optional. Diamandis knows this—and he’s using SynBioBeta as his TED stage to get the message out.

We’re talking about an age when we can write DNA the way we write software. And just like we needed platforms like AWS to make the internet scalable, we’re going to need platforms like Ginkgo Bioworks or Insitro to make healthspan scalable. This is where Diamandis thrives—in the gaps between fields, where biologists and coders have to learn each other’s languages or risk becoming irrelevant.

At his Longevity Platinum Trip, participants don’t just sit through PowerPoints. They visit labs where scientists are reprogramming epigenetic clocks. They talk to CEOs about editing genes like some people edit Google Docs. It’s a reminder that the breakthroughs aren’t decades away—they’re just a regulatory ruling, a funding round, or a partnership away.

And yes, the science is mind-bending. But Diamandis is less interested in the complexity than in the clarity: How do we build a future where we live longer, better, and cheaper—and make that available to everyone?

The Next Billion-Dollar Industry Might Be Your Mitochondria

There’s a geopolitical undercurrent to all of this. Countries that get longevity right won’t just have healthier populations—they’ll have a demographic advantage. Imagine a 70-year-old workforce with the biology of a 45-year-old. That’s not just productivity—it’s national resilience.

Diamandis sees synthetic biology not just as a set of tools, but as the next industrial revolution. Just like electricity rewired everything from cities to factories, synthetic biology will rewire everything from insurance models to retirement plans. And at the center of that future? Longevity.

That’s why his SynBioBeta keynote is one of the most anticipated of the year. The working title is still under wraps, but you can bet it’ll touch on everything from cellular reprogramming to the economics of 100-year lifespans. And like always, he’ll ask the big, uncomfortable questions: If we can live longer, should we? And what does it mean for society if aging becomes optional?

We’re at the beginning of a new narrative. It’s no longer “How long can we live?” but “How well can we live—and how can we share that with the world?” Peter Diamandis doesn’t have all the answers. But at SynBioBeta 2025, he’s making sure we ask the right questions.